Discriminating cross-reactivity in polyclonal IgG1 responses against SARS-CoV-2 variants of concern

Publication date

2022-10-15

Authors

van Rijswijck, Danique Maria HendrinaISNI 0000000507774540
Bondt, AlbertORCID 0000-0002-0985-7903ISNI 000000049247873X
Hoek, MaxISNI 0000000492869909
van der Straten, Karlijn
Caniels, Tom G
Poniman, Meliawati
Eggink, Dirk
Reusken, Chantal
de Bree, Godelieve J
Sanders, Rogier W

Editors

Advisors

Supervisors

Document Type

Article
Open Access logo

License

cc_by

Abstract

Existing assays to measure antibody cross-reactivity against different SARS-CoV-2 spike (S) protein variants lack the discriminatory power to provide insights at the level of individual clones. Using a mass spectrometry-based approach we are able to monitor individual donors' IgG1 clonal responses following a SARS-CoV-2 infection. We monitor the plasma clonal IgG1 profiles of 8 donors who had experienced an infection by either the wild type Wuhan Hu-1 virus or one of 3 VOCs (Alpha, Beta and Gamma). In these donors we chart the full plasma IgG1 repertoires as well as the IgG1 repertoires targeting the SARS-CoV-2 spike protein trimer VOC antigens. The plasma of each donor contains numerous anti-spike IgG1 antibodies, accounting for <0.1% up to almost 10% of all IgG1s. Some of these antibodies are VOC-specific whereas others do recognize multiple or even all VOCs. We show that in these polyclonal responses, each clone exhibits a distinct cross-reactivity and also distinct virus neutralization capacity. These observations support the need for a more personalized look at the antibody clonal responses to infectious diseases.

Keywords

Antibodies, Neutralizing, Antibodies, Viral, Antigens, Viral, COVID-19, Humans, Immunoglobulin G, SARS-CoV-2, Spike Glycoprotein, Coronavirus, SDG 3 - Good Health and Well-being

Citation

van Rijswijck, D M H, Bondt, A, Hoek, M, van der Straten, K, Caniels, T G, Poniman, M, Eggink, D, Reusken, C, de Bree, G J, Sanders, R W, van Gils, M J & Heck, A J R 2022, 'Discriminating cross-reactivity in polyclonal IgG1 responses against SARS-CoV-2 variants of concern', Nature Communications, vol. 13, no. 1, 6103. https://doi.org/10.1038/s41467-022-33899-1